<DOC>
	<DOC>NCT01495845</DOC>
	<brief_summary>The purpose of this study is to determine the feasibility of pharmacogenomics testing in a community pharmacy using clopidogrel as an example. The investigators hypothesize that this testing is feasible in this setting.</brief_summary>
	<brief_title>Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy</brief_title>
	<detailed_description>To determine if the study is feasible, we will examine the change in patient perception of pharmacogenomics testing (before and after the study), the percentage of patients interested in this service, the response rate of providers to pharmacist recommendations, the pharmacist time requirement, and reimbursement rate for pharmacist services.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemic Attack, Transient</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Prescribed clopidogrel (Plavix) by their prescriber Aged 18 or older Currently on clopidogrel therapy for one of the following indicated uses: postACS, Recent PCI with stenting, History of TIA or stroke Are unable to complete study materials (surveys) with or without assistance, including nonEnglish speaking patients Are taking clopidogrel for a reason other than stated in inclusion criteria Are pregnant or nursing Have an allergy to aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>pharmacogenomics</keyword>
	<keyword>feasibility</keyword>
	<keyword>community pharmacy</keyword>
	<keyword>personalized medicine</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>Plavix</keyword>
</DOC>